Multistep and single-step resistance selection studies were performed with razupenem, linezolid, and vancomycin against 10 methicillin (meticillin)-resistant and -susceptible Staphylococcus aureus strains. After 20 daily subcultures, razupenem yielded only clones with MICs of >4 g/ml in one strain (8 g/ml) whose parent's MIC was already 4 g/ml. After 18 to 49 passages in 6/10 strains, razupenem MICs rose from 0.016 to 2 g/ml (parents) to 0.125 to 8 g/ml (with clones stable after 10 drug-free subcultures). Single-step mutant selection frequencies were similarly low for razupenem and comparators.
Staphylococcus aureus is becoming increasingly resistant to antibiotics. Additionally, the majority of methicillin (meticillin)-resistant S. aureus (MRSA) (and also some methicillinsusceptible [MSSA]) strains are resistant to all currently available quinolones (1) . Heterogeneous vancomycin-intermediate S. aureus (hVISA) and vancomycin-intermediate S. aureus (VISA) strains (1, 5, 7, 8, 11, 12) are increasingly reported, and recently, nine vancomycin-resistant S. aureus (VRSA) strains have been described (1; M. Rybak, personal communication). Two recent papers emphasize the recent spread of VISA strains in Turkey (12) and France (7) . Recently, Rybak et al. (11) have indicated, with macro Etest and population analysis testing, that the incidence of hVISA strains has increased over the past 22 years for an overall incidence of 2.2%. Yusof et al. (17) have recently described a double-sided vancomycin/teicoplanin macro Etest strip which accurately differentiates between hVISA and VISA strains. Utilization of this method will increase reports of the incidence of hVISA and VISA strains. As of this time, the pathogenicity of VRSA strains awaits confirmation.
The situation has become further complicated by the appearance and rapid spread, especially in the United States, of community-acquired MRSA strains, which are especially virulent possibly by virtue of the production of Panton-Valentine leukocidin (1) . Although these strains are currently more drug susceptible than are hospital-acquired strains, this situation will not remain the same, and increased resistance will develop. Additionally, treatment of the community-acquired MRSA strains with glycopeptides will increase the selective pressure leading to nonsusceptibility to vancomycin and teicoplanin. There is therefore an urgent need for nonglycopeptide drugs with which to treat MRSA strains. Recently, we and others have also documented clinical development of daptomycin resistance after daptomycin therapy (8) .
Razupenem (also formerly known as SM-216601, SMP-601, PZ-601, and PTZ601) ( Fig. 1 ) is a new experimental broadspectrum 2-(4-arylthiazol-2-ylthio)-1␤-methylcarbapenem derivative with enhanced activity against gram-positive organisms, including staphylococci, enterococci, and MRSA (9, 10, 14, 15) . This study examines the antistaphylococcal activity of razupenem compared to the activities of vancomycin and linezolid, by single-and multistep mutant selection analysis.
Ten isolates were tested by multistep and single-step resistance selection analysis. These included eight MRSA strains, comprising two each of MSSA, MRSA, hVISA, VISA, and VRSA isolates. All organisms except VRSA 509 (Michigan) were recent isolates from patients at Hershey Medical Center. Razupenem powder was obtained from Protez Pharmaceuticals, Inc., Malvern, PA.
The CLSI standard macrodilution method was used for initial MICs (6) . Serial passages were performed daily in Mueller-Hinton broth for each strain in subinhibitory concentrations of all antimicrobials. For each subsequent daily passage, an inoculum was taken from the tube 1 to 2 dilutions below the MIC that matched the turbidity of a growth control tube. This inoculum was used to determine the next MIC. Daily passages (minimum of 14) were performed until a significant increase in MIC (Ͼ4-fold) was obtained. Stability of the acquired resis- Vancomycin Ͼ64 NT NT a Pass., number of daily passages. Boldface text indicates stable clones defined to have an MIC after the drug-free passages within Ϯ1 of the MIC before the drug-free passages. NT, not tested at MICs of Ն64 g/ml. b Razupenem is the only drug for which passages were continued after the MIC was more than four times the initial MIC. (3, 4) . A stable clone is defined as having an MIC after the drug-free passages within Ϯ1 of the MIC before the drug-free passages. Only for razupenem clones were passages continued for the maximum of 50 days, regardless of MIC, as seen in Table 1 . For multistep testing, confirmation of parent and resistant clones was done by pulsed-field gel electrophoresis (3, 4) . For single-step studies, very high inocula (1 ϫ 10 10 to 1 ϫ 10 11 CFU/ml) of the 10 isolates on cation-adjusted Mueller-Hinton plates were exposed to each drug at 2ϫ, 4ϫ, and 8ϫ MIC. Each plate contained 20 ml medium and was inoculated with 50-l aliquots of the above-mentioned high inocula. To ensure that colonies could be quantitated (0 to 300 colonies/ plate), dilutions of the inoculum were also made, resulting in a minimum of three plates per drug concentration. The frequency of spontaneous mutations was calculated at each MIC multiple for each strain after incubation of plates for 48 h (4) .
Results of the multistep resistance selection studies are presented in Table 1 . As can be seen, parental MICs (g/ml) were as follows: razupenem, 0.016 to 4; vancomycin, 2 to Ͼ64; linezolid, 2 to 4. Razupenem yielded no resistant clones (Ͼ4-fold increase) after 15 days (Table 1 ). After 20 daily subcultures, razupenem yielded only clones with MICs of Ͼ4 g/ml (preliminary susceptibility breakpoint of Յ4 g/ml obtained by population pharmacokinetics and Monte Carlo simulation [2] ) in one strain (SA618; 8 g/ml) ( Table 1 ) whose parent's MIC was 4 g/ml. This MIC remained stable throughout an additional 30 days (the maximum number of passages). After 18 to 49 days, in 6 of 10 strains, razupenem MICs rose from 0.016 to 2 g/ml (parents) to 0.125 to 8 g/ml (stable clones after 10 drug-free subcultures) ( Table 1 ). Of these six resistant clones, two yielded razupenem MICs of Ͼ4 g/ml. Linezolid yielded resistant clones after 15 to 48 days in 4 of 10 strains with MICs rising from 2 to 4 g/ml (parents) to 16 to 32 g/ml (stable clones) ( Table 1) . Vancomycin selected no resistant clones (Ͼ4-fold increase) in all eight strains tested (MICs of Ն64 g/ml were not tested). MICs of vancomycin against the tested strains rose from 2 to 8 g/ml (parents) to 4 to 8 g/ml after 50 days ( Table 1) . No cross-resistance was found with any clone/ antimicrobial combination ( Table 1) .
Results of the single-step resistance selection studies are presented in Table 2 . Mutant selection frequencies for razupenem ranged from Ͻ4.0 ϫ 10 Ϫ11 to 6.0 ϫ 10 Ϫ6 at 2ϫ MIC to Ͻ3.3 ϫ 10 Ϫ11 to 6.7 ϫ 10 Ϫ9 at 8ϫ MIC. These frequencies were equivalent to those for the existing carbapenems (imipenem, meropenem) against Pseudomonas aeruginosa (13, 16) . Comparator values were similar: vancomycin, Ͻ3.3 ϫ 10 Ϫ11 to Ͼ1.0 ϫ 10 Ϫ8 at 2ϫ MIC to Ͻ3.3 ϫ 10 Ϫ11 to Ͻ5.0 ϫ 10 Ϫ10 at 8ϫ MIC; and linezolid, Ͻ3.7 ϫ 10 Ϫ11 to Ͻ3.3 ϫ 10 Ϫ10 at 2ϫ MIC to Ͻ 3.7 ϫ 10 Ϫ11 to Ͻ3.3 ϫ 10 Ϫ10 at 8ϫ MIC.
Previous reports of razupenem (also known previously as SM-216601, SMP-601, PZ-601, and PTZ601) have reported improved activity against staphylococci and Enterococcus faecium, with MICs against MRSA ranging from 0.06 to 2 g/ml (MIC 90 , 2 g/ml). The compound is also potent against streptococci, Haemophilus influenzae, Moraxella catarrhalis, and Enterobacteriaceae such as Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis (9, 14, 15 ). Razupenem is not compro-mised (like other ␤-lactams) by low temperature or high salt concentrations (10) . Additionally, razupenem shows better pharmacokinetics in animals, suggesting a favorable pharmacokinetic profile in humans, with a longer half-life, than do available carbapenems (15) . In a murine model of hematogenous bronchopneumonia caused by MRSA and VISA, treatment with razupenem (MICs of 2 g/ml for test strains) resulted in a significant decrease in the number of viable bacteria, a higher survival rate, and less marked inflammatory changes in the group treated with razupenem than in the group treated with vancomycin (9) .
The current study shows MICs against MRSA similar to those reported previously (9, 14, 15) , and especially to those reported by Livermore and Warner (10) who obtained, irrespective of temperature and NaCl, razupenem MICs of 4 g/ml in some strains. Our studies also indicate that razupenem has confirmed activity versus MRSA at a preliminary breakpoint of Յ4 g/ml (2) and low rates of spontaneous mutations on single-step selection. Although razupenem had a low propensity to select for mutations after 20 daily subcultures, 6 of the 10 strains tested yielded clones with increased MICs, two with MICs above the preliminary susceptibility breakpoint of Յ4 g/ml, at between 20 and 50 daily subcultures. The significance of these findings remains to be determined in the clinical setting. 
